NewVale Capital
A growth equity investment firm focused on supporting the services architecture underpinning the life science industry.
NewVale invests in services, software, and technologies – the infrastructure of life sciences – that have a proven return on investment for pharmaceutical customers, helping to accelerate timelines, reduce costs and improve quality.
With nearly $200 million total under management, the firm makes investments of between $10 and $50 million in growth companies across the continuum of the pharmaceutical value chain, including discovery, clinical, manufacturing, regulatory and commercialization.
Latest NewVale Capital News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze